Drug Type Small molecule drug |
Synonyms JC-5411, Abrassin |
Target |
Action inhibitors, stimulants |
Mechanism HSF1 inhibitors(heat shock transcription factor 1 inhibitors), Nrf2 stimulants(Nuclear factor erythroid 2-related factor 2 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC9H9NS |
InChIKeyIZJDOKYDEWTZSO-UHFFFAOYSA-N |
CAS Registry2257-09-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Phenethyl Isothiocyanate | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Prostate Carcinoma | Phase 2 | China | 15 Dec 2021 | |
Prostatic Hyperplasia | Phase 2 | China | 04 Apr 2014 | |
Tobacco Use Disorder | Phase 2 | United States | 01 Feb 2009 | |
Lung Cancer | Phase 2 | United States | 01 Feb 2009 | |
Advanced Malignant Solid Neoplasm | Phase 1 | China | 13 Dec 2023 | |
Squamous Cell Carcinoma of Head and Neck | Preclinical | United States | 15 Jun 2022 | |
Colonic Cancer | Preclinical | United States | 01 May 2007 | |
Prostatic Cancer | Preclinical | United States | 01 May 2007 |